M1069 (free base) is an orally active and selective dual antagonist for the A2A and A2B adenosine receptors, demonstrating over 100-fold selectivity compared to A1 and A3 receptors. It mitigates the immune-suppressive effects of adenosine and shows anti-tumor properties [1] [2] [3].